-Advertisement-
-Advertisement-
Lupus Nephritis

Phase 2 TULIP-LN Trial: Anifrolumab shows efficacy in treating lupus nephritis
The Phase 2 randomized, double-blind TULIP-LN trial evaluating the safety and efficacy of anifrolumab in treating active lupus nephritis (LN) has shown promising results through the second year of the study, according to a study. Patients received intravenous anifrolumab doses, with the initial 3 doses at 900 mg followed by...
Read More-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement=-
-Advertisement-
-Advertisement-
-Advertisement-
Stay Connected! Join Our Newsletter
Contact
Grandin Library Building
Six Leigh Street
Clinton, New Jersey 08809
+908-505-8899
[email protected]
© 2023 Med Journal 360™ is a trademark of International Healthcare Media, LLC. All rights Reserved